Beijing Tiantan Bio share transfer boosts controlling shareholder's direct stake

Beijing Tiantan Biological Products Co., Ltd. announced that its controlling shareholder, China National Biotec Group Co., Ltd. (China Biotec), will receive a gratuitous transfer of 18,802,366 shares, representing 0.95% of the company's total share capital, from its wholly-owned subsidiary, Beijing Institute of Biological Products Co., Ltd. This move has been approved by the ultimate controlling entity, China National Pharmaceutical Group Corporation.

Following the transfer, China Biotec's direct shareholding in Beijing Tiantan Biological Products will increase to 921,302,854 shares, or 46.59% of the total share capital. Beijing Institute of Biological Products Co., Ltd. will no longer hold any shares in the company.

The aggregate shareholding of China Biotec and its concerted parties will remain unchanged at 991,120,289 shares, representing 50.12% of the company's total share capital. This gratuitous transfer will not alter the controlling shareholder or the ultimate beneficial owner of Beijing Tiantan Biological Products and does not involve a tender offer. The company will disclose further progress on the share transfer as necessary.